Melanotan II · research summary

Melanotan Tanning Injection: A Rare Cause of Priapism.

Sexual medicine · 2021. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Case report
“We describe in this case report a patient presenting with acute ischemic priapism after subcutaneous injection of melanotan II.”

Subjects

A 55-year-old Caucasian man
“A 55-year-old Caucasian man presented to our institution's emergency department with a chief complaint of painful, sustained penile erection of 30 hours of duration on arrival.”

Sample size

1
“We describe in this case report a patient presenting with acute ischemic priapism after subcutaneous injection of melanotan II.”

Duration

15 weeks follow-up
“At 15 week follow-up, he reported a degree of new onset erectile dysfunction, with rigidity 4/10 and corpora fibrosis on examination, with no penile curvature.”

Reported findings

The patient developed acute ischemic priapism after subcutaneous injection of melanotan II, which was managed with penoscrotal decompression after initial conservative measures failed.
“After failing initial management, the patient underwent operative management with penoscrotal decompression, a promising alternative technique for the management of refractory ischemic priapism.”
At 15-week follow-up, the patient reported new onset erectile dysfunction and corpora fibrosis.
“At 15 week follow-up, he reported a degree of new onset erectile dysfunction, with rigidity 4/10 and corpora fibrosis on examination, with no penile curvature.”
Priapism after melanotan II injection has only been reported in the literature twice before this case.
“Priapism after melanotan II injection has only been reported in the literature twice before.”

Limitations stated by the authors

The literature related to management of priapism is not extensive, mostly consisting of case reports and small case series rather than prospective studies.
“The literature related to management of priapism is not extensive, mostly consisting of case reports and small case series rather than prospective studies.”

Source: PubMed 33460908 · DOI 10.1016/j.esxm.2020.100298 · all study summaries

Reported findings

The patient developed acute ischemic priapism after subcutaneous injection of melanotan II, which was managed with penoscrotal decompression after initial conservative measures failed.

“After failing initial management, the patient underwent operative management with penoscrotal decompression, a promising alternative technique for the management of refractory ischemic priapism.”

At 15-week follow-up, the patient reported new onset erectile dysfunction and corpora fibrosis.

“At 15 week follow-up, he reported a degree of new onset erectile dysfunction, with rigidity 4/10 and corpora fibrosis on examination, with no penile curvature.”

Priapism after melanotan II injection has only been reported in the literature twice before this case.

“Priapism after melanotan II injection has only been reported in the literature twice before.”

Limitations stated by the authors

The literature related to management of priapism is not extensive, mostly consisting of case reports and small case series rather than prospective studies.

“The literature related to management of priapism is not extensive, mostly consisting of case reports and small case series rather than prospective studies.”